Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Randomised, Double-blind, Placebo-controlled, Single-dose, Dose-ranging Study of the Efficacy and Safety of MEDI4893, a Human Monoclonal Antibody Against Staphylococcus Aureus Alpha Toxin in Mechanically Ventilated Adult Subjects

Trial Profile

A Phase 2 Randomised, Double-blind, Placebo-controlled, Single-dose, Dose-ranging Study of the Efficacy and Safety of MEDI4893, a Human Monoclonal Antibody Against Staphylococcus Aureus Alpha Toxin in Mechanically Ventilated Adult Subjects

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 25 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Suvratoxumab (Primary)
  • Indications Bacterial infections; Nosocomial pneumonia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SAATELLITE
  • Sponsors AstraZeneca; MedImmune
  • Most Recent Events

    • 16 Apr 2019 Results evaluating efficacy, safety, pharmacokinetics, immunogenicity of Suvratoxumab presented at the 29th European Congress of Clinical Microbiology and Infectious Diseases
    • 11 Apr 2019 According to an Innovative Medicines Initiative media release, trial results will be presented at the ECCMID meeting in Amsterdam on April 16th and at the ATS meeting in Dallas on May 20th.
    • 11 Apr 2019 According to an Innovative Medicines Initiative media release, the trial was led by Bruno Francois from Limoges University Hospital (France) as Coordinating Principal Investigator, and Hasan Jafri from AstraZeneca as the industry scientific lead.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top